ReWalk Robotics Reports Third Quarter 2014 Financial Results Revenue up 277% year-over-year to $1.5 million Successful completion of IPO raises $38.7 million, net ReWalk becomes first and only exosk

ReWalk Robotics Reports Third Quarter

2014 Financial Results

Revenue up 277% year-over-year to $1.5

Successful completion of IPO raises $38.7

ReWalk becomes first and only exoskeleton

cleared by the FDA for use in the U.S.

YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, November 13, 2014

- ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk," or "the Company") today announced its financial

results for the three- and nine-month periods ended September 30, 2014. Highlights of and subsequent to the third quarter 2014

"We achieved several significant

milestones during the third quarter of 2014 that allowed us to bring our revolutionary technology to a broader group of individuals

with spinal cord injuries. Our market-leading position was strengthened this quarter when we received FDA clearance as the only

powered exoskeleton that can be legally marketed in the U.S.," said Larry Jasinski, Chief Executive Officer. "We are

excited to be able to provide wheelchair-bound individuals with access to the ReWalk system for daily use at home and in their

communities, where they need it most."

"We also secured reimbursement on

a case-by-case basis for ReWalk personal systems in the U.S. and Germany, paving the way for additional favorable coverage decisions

by other major insurers. Importantly, we strengthened our balance sheet with the successful completion of our IPO. Building on

the momentum generated during the third quarter, we will continue to aggressively execute our strategy in the U.S., Europe and

other geographies," Jasinski concluded.

Third Quarter 2014 Financial

Total revenues were $1.5 million for

the third quarter of 2014, up 277% compared with $408,000 in the third quarter of 2013, due to higher sales of ReWalk systems during

the third quarter of 2014. In the third quarter of 2014, 26 ReWalk systems were sold compared with six ReWalk systems sold in the

Gross profit improved to $331,000 as

compared to a gross loss of $20,000 in the third quarter of 2013, reflecting higher sales in the 2014 period coupled with manufacturing

economies of scale. All ReWalk systems sold in third quarter of 2014 consisted of systems purchased from Sanmina.

Total operating expenses in the third

quarter of 2014 were $8.1 million, compared with $2.2 million in the third quarter of 2013. The increase reflects non-cash share-based

compensation expenses of $4.5 million in third quarter of 2014 and incremental investment in sales, marketing, and research and

development resources. Excluding non-cash share-based compensation expenses, total operating expenses were $3.6 million during

the third quarter of 2014.

Operating loss was $7.8 million for

the third quarter of 2014 compared with $2.2 million during the prior year quarter. Non-GAAP operating loss, excluding non-cash

share-based compensation expenses, was $3.3 million for the third quarter of 2014.

Net loss was $6.4 million for the third

quarter of 2014 compared with $3.3 million in the prior year quarter. Non-GAAP net loss for the third quarter of 2014 was $3.5

million compared with non-GAAP net loss of $2.2 million in the prior year quarter.

A reconciliation of operating loss

and net loss to non-GAAP operating loss and non-GAAP net loss is included at the end of this press release.

Nine Month 2014 Financial Highlights

Total revenues were $2.5 million for

the nine months ended September 30, 2014, up 106% compared with $1.2 million during the nine months ended September 30, 2013, due

to higher sales of ReWalk systems during the 2014 period. In the 2014 nine-month period, 42 ReWalk systems were sold compared with

19 ReWalk systems sold during the same period in 2013.

Gross profit improved to a loss of

$92,000 as compared to a loss of $297,000 for the nine months ended September 30, 2013, reflecting higher sales in the 2014 period

coupled with manufacturing economies of scale. For the nine months ended September 30, 2014, cost of revenues consisted primarily

of ReWalk systems purchased from Sanmina, as well as expenses related to the transition of our manufacturing activities to Sanmina.

For the nine months ended September 30, 2013, cost of revenues consisted primarily of ReWalk systems manufactured by the

Total operating expenses during the

nine months ended September 30, 2014, were $14.6 million compared with $5.7 million in the prior year period, reflecting non-cash

share-based compensation expenses of $4.9 million in the nine months ended September 30, 2014, and increased investment in sales,

marketing, and research and development resources. Excluding the non-cash share-based compensation expenses, total operating expenses

were $9.7 million compared with $5.6 million in the prior year period.

Operating loss for the nine months

ended September 30, 2014, was $14.6 million compared with $6.0 million during the prior year period. Excluding non-cash compensation

expenses, operating loss was $9.8 million for the nine months ended September 30, 2014, compared with $5.9 million during the nine

months ended September 30, 2013.

Net loss for the nine months ended

September 30, 2014 was $16.2 million compared with $8.7 million during the nine months ended September 30, 2013. Non-GAAP net loss

was $10.1 million for the nine months ended September 30, 2014, compared with non-GAAP net loss of $6.0 million during the nine

months ended September 30, 2013.

A reconciliation of operating loss

and net loss to non-GAAP operating loss and non-GAAP net loss is included at the end of this press release.

As of September 30, 2014, ReWalk had

$47.7 million in cash and cash equivalents and short-term deposits. During the three months ended September 30, 2014, the Company

raised $38.7 million, net, from its initial public offering, $12.8 million from a pre-IPO financing round, and $1.1 million from

the exercise of warrants to purchase convertible preferred shares.

Cash used in operating activities was

$5.8 million and $12.6 million during the three- and nine-month periods ended September 30, 2014, respectively, compared with $2.2

million and $6.1 million in the respective prior year periods.

ReWalk management will host its third

quarter conference call as follows:

A telephone replay will be available

shortly after the completion of the call for two weeks at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The passcode

for the replay is 27344193.

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. (formerly Argo

Medical Technologies Ltd.) develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury.

ReWalk's mission is to fundamentally change the health and life experiences of individuals with spinal cord injury. Founded

in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit http://www.rewalk.com.

Forward Looking Statements

This press release contains forward-looking

information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and other securities laws. Forward-looking

statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s),"

"will," "may," "intends," "anticipate(s)," "look forward," "upcoming,"

"plan," "enables," "potentially," "entitles," and similar expressions are intended

to identify forward-looking statements. These statements include, but are not limited to, statements regarding the anticipated

revenues and underlying sales for the fourth quarter of 2014; future availability of reimbursement for ReWalk in Germany and the

United States; and the successful and timely achievement of favorable coverage decisions for ReWalk by additional major insurers.

All such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond

the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected

by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to the following:

the market for medical exoskeletons is new and unproven, and important assumptions about the potential market for our products

may be inaccurate; the Company has a limited operating history upon which you can evaluate our business plan and prospects; if

we are unable to expand our sales, marketing and training infrastructure, we may fail to increase our sales; the health benefits

of ReWalk have not been substantiated by long-term clinical data, which could limit sales; the Company may fail to secure or retain

adequate coverage or reimbursement for ReWalk by third-party payors; the Company depends on a single third-party to manufacture